Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (29)
Brian G. Hunt, Levi H. Fox, James C. Davis, Angelle Jones, Zhixin Lu & Susan E. Waltz. (2023) An Introduction and Overview of RON Receptor Tyrosine Kinase Signaling. Genes 14:2, pages 517.
Crossref
Crossref
Karina Patasova, Ingrid E. Lundberg & Marie Holmqvist. (2022)
Genetic Influences in
Cancer‐Associated
Myositis
. Arthritis & Rheumatology 75:2, pages 153-163.
Crossref
Crossref
Saara Koivusalo, Anette Schmidt, Aki Manninen & Tomasz Wenta. (2022) Regulation of Kinase Signaling Pathways by α6β4-Integrins and Plectin in Prostate Cancer. Cancers 15:1, pages 149.
Crossref
Crossref
Omid Zarei, Stéphane L. Raeppel & Maryam Hamzeh-Mivehroud. (2022) An alignment-independent three-dimensional quantitative structure–activity relationship study on ron receptor tyrosine kinase inhibitors. Journal of Bioinformatics and Computational Biology 20:03.
Crossref
Crossref
Sasha J. Ruiz-Torres, Jennifer R. Bourn, Nancy M. Benight, Brian G. Hunt, Carissa Lester & Susan E. Waltz. (2021) Macrophage-mediated RON signaling supports breast cancer growth and progression through modulation of IL-35. Oncogene 41:3, pages 321-333.
Crossref
Crossref
Wei Lin, Xiaofeng Wan, Anjiang Sun, Meng Zhou, Xu Chen, Yanling Li, Zixi Wang, Hailiang Huang, Hongwu Li, Xianguo Chen, Juan Hua & Xiaojun Zha. (2021) RUNX1/EGFR pathway contributes to STAT3 activation and tumor growth caused by hyperactivated mTORC1. Molecular Therapy - Oncolytics 23, pages 387-401.
Crossref
Crossref
Shao-Long Chen, Guo-Ping Wang, Dan-Rong Shi, Shu-Hao Yao, Ke-Da Chen & Hang-Ping Yao. (2021) RON in hepatobiliary and pancreatic cancers: Pathogenesis and potential therapeutic targets. World Journal of Gastroenterology 27:20, pages 2507-2520.
Crossref
Crossref
Corinna Preusse, Pascale Eede, Lucie Heinzeling, Kiara Freitag, Randi Koll, Waltraud Froehlich, Udo Schneider, Yves Allenbach, Olivier Benveniste, Anne Schänzer, Hans‐Hilmar Goebel, Werner Stenzel & Josefine Radke. (2021)
NanoString technology distinguishes anti‐TIF‐1γ
+
from anti‐Mi‐2
+
dermatomyositis patients
. Brain Pathology 31:3.
Crossref
Crossref
Yuting Zhou, Xingwei Xu, Fei Wang, Huan He & Baohui Qi. (2021) Discovery of 4-((4-(4-(3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)ureido)-2-fluorophenoxy)-6-methoxyquinolin-7-yl)oxy)-N,N-diethylpiperidine-1-carboxamide as kinase inhibitor for the treatment of colorectal cancer. Bioorganic Chemistry 106, pages 104511.
Crossref
Crossref
Amit Gupta, Sandhya Yadav, Archana PT, Jharna Mishra, Atul Samaiya, Rajendra Kumar Panday & Sanjeev Shukla. (2020) The HNRNPA2B1–MST1R–Akt axis contributes to epithelial-to-mesenchymal transition in head and neck cancer. Laboratory Investigation 100:12, pages 1589-1601.
Crossref
Crossref
Yuting Zhou, Xingwei Xu, Fei Wang, Huan He, Guowei Gong, Li Xiong & Baohui Qi. (2020) Identification of novel quinoline analogues bearing thiazolidinones as potent kinase inhibitors for the treatment of colorectal cancer. European Journal of Medicinal Chemistry 204, pages 112643.
Crossref
Crossref
Brian G. Hunt, Christina A. Wicker, Jennifer R. Bourn, Elyse E. Lower, Vinita Takiar & Susan E. Waltz. (2020) MST1R (RON) expression is a novel prognostic biomarker for metastatic progression in breast cancer patients. Breast Cancer Research and Treatment 181:3, pages 529-540.
Crossref
Crossref
Philipp Berning, Carolin Hennemann, Claudia Tulotta, Christiane Schaefer, Birgit Lechtape, Marc Hotfilder, Yassmine El Gourari, Heribert Jürgens, Ewa Snaar-Jagalska, Georg Hempel, Uta Dirksen & Jenny Potratz. (2020) The Receptor Tyrosine Kinase RON and Its Isoforms as Therapeutic Targets in Ewing Sarcoma. Cancers 12:4, pages 904.
Crossref
Crossref
Chen-Yu Hu, Xiang-Ming Xu, Bo Hong, Zhi-Gang Wu, Yun Qian, Tian-Hao Weng, Yi-Zhi Liu, Tao-Ming Tang, Ming-Hai Wang & Hang-Ping Yao. (2019) Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer. Frontiers in Oncology 9.
Crossref
Crossref
Jung Sun Park, Hoon-In Choi, Dong-Hyun Kim, Chang Seong Kim, Eun Hui Bae, Seong Kwon Ma & Soo Wan Kim. (2019) RON Receptor Tyrosine Kinase Regulates Epithelial Mesenchymal Transition and the Expression of Pro-Fibrotic Markers via Src/Smad Signaling in HK-2 and NRK49F Cells. International Journal of Molecular Sciences 20:21, pages 5489.
Crossref
Crossref
Nicholas E. Brown, Andrew M. Paluch, Madison A. Nashu, Kakajan Komurov & Susan E. Waltz. (2018) Tumor Cell Autonomous RON Receptor Expression Promotes Prostate Cancer Growth Under Conditions of Androgen Deprivation. Neoplasia 20:9, pages 917-929.
Crossref
Crossref
Sasha J. Ruiz-Torres, Nancy M. Benight, Rebekah A. Karns, Elyse E. Lower, Jun-Lin Guan & Susan E. Waltz. (2017) HGFL-mediated RON signaling supports breast cancer stem cell phenotypes via activation of non-canonical β-catenin signaling. Oncotarget 8:35, pages 58918-58933.
Crossref
Crossref
J Chakedis, R French, M Babicky, D Jaquish, H Howard, E Mose, R Lam, P Holman, J Miyamoto, Z Walterscheid & A M Lowy. (2015) A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells. Oncogene 35:25, pages 3249-3259.
Crossref
Crossref
Najme Faham & Alana L. Welm. (2016) RON Signaling Is a Key Mediator of Tumor Progression in Many Human Cancers. Cold Spring Harbor Symposia on Quantitative Biology 81, pages 177-188.
Crossref
Crossref
Franck Raeppel, Stéphane L. Raeppel & Eric Therrien. (2015) Design, synthesis and RON receptor tyrosine kinase inhibitory activity of new head groups analogs of LCRF-0004. Bioorganic & Medicinal Chemistry Letters 25:18, pages 3810-3815.
Crossref
Crossref
Stéphane L. Raeppel, Eric Therrien & Franck Raeppel. (2015) Design and synthesis of constrained analogs of LCRF-0004 as potent RON tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 25:17, pages 3706-3710.
Crossref
Crossref
Stéphane L. Raeppel, Franck Raeppel & Eric Therrien. (2015) Design and synthesis of close analogs of LCRF-0004, a potent and selective RON receptor tyrosine kinase inhibitor. Bioorganic & Medicinal Chemistry Letters 25:12, pages 2527-2531.
Crossref
Crossref
William D. Stuart, Nicholas E. Brown, Andrew M. Paluch & Susan E. Waltz. (2015) Loss of Ron receptor signaling leads to reduced obesity, diabetic phenotypes and hepatic steatosis in response to high-fat diet in mice. American Journal of Physiology-Endocrinology and Metabolism 308:7, pages E562-E572.
Crossref
Crossref
Xin Wang, Neela Yennawar & Pamela A Hankey. (2014) Autoinhibition of the Ron receptor tyrosine kinase by the juxtamembrane domain. Cell Communication and Signaling 12:1.
Crossref
Crossref
Kyle E Landgraf, Micah Steffek, Clifford Quan, Jeffrey Tom, Christine Yu, Lydia Santell, Henry R Maun, Charles Eigenbrot & Robert A Lazarus. (2014) An allosteric switch for pro-HGF/Met signaling using zymogen activator peptides. Nature Chemical Biology 10:7, pages 567-573.
Crossref
Crossref
Shao-Chun Wang. (2014) PCNA: a silent housekeeper or a potential therapeutic target?. Trends in Pharmacological Sciences 35:4, pages 178-186.
Crossref
Crossref
John Watson, Brian J. Arey & Andrew Alt. 2014. Biased Signaling in Physiology, Pharmacology and Therapeutics. Biased Signaling in Physiology, Pharmacology and Therapeutics
137
172
.
Steven E. Kauder, Lydia Santell, Elaine Mai, Lilyan Y. Wright, Elizabeth Luis, Elsa N. N'Diaye, Jeff Lutman, Navneet Ratti, Susan M. Sa, Henry R. Maun, Eric Stefanich, Lino C. Gonzalez, Robert R. Graham, Lauri Diehl, William A. Faubion, Mary E. Keir, Judy Young, Amitabha Chaudhuri, Robert A. Lazarus & Jackson G. Egen. (2013) Functional Consequences of the Macrophage Stimulating Protein 689C Inflammatory Bowel Disease Risk Allele. PLoS ONE 8:12, pages e83958.
Crossref
Crossref
Sharad Sharma, Jun-Ying Zeng, Chun-Mei Zhuang, Yong-Qing Zhou, Hang-Ping Yao, Xing Hu, Ruiwen Zhang & Ming-Hai Wang. (2013) Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents. Molecular Cancer Therapeutics 12:5, pages 725-736.
Crossref
Crossref